Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,711.00+1.29%ETH$2,287.21+1.77%GOLD$3,940.20-0.74%OIL$96.76+0.31%
Smart Investors Daily
SID Premium
Cerus Corporation logo

NASDAQ · CERS

Cerus Corporation

Healthcare · Medical - Devices

$2.36

Down-$0.02 (-0.85%)

Updated Nov 3, 2026, 10:35 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
414.62M
P/E ratio
-21.89
Dividend yield
0.00%
52-week range
$1.38 – $3.47
Volume
3.99M
Avg. volume
1.42M

Price performance · CERS

CERS price history

1M range · 0 trading sessions · Daily adjusted prices

CERS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CERS news

The latest Smart Investors Daily articles mentioning CERS.

Stock researchCompany · Overview

CERS research

Overview

Company profile and research snapshot.

Company profile

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
CERS recent ratings
DateFirmRatingTarget
Aug 20, 2026Freedom BrokerBuy—
May 1, 2026BTIGBuy—
Feb 21, 2025Cantor FitzgeraldOverweight—
Oct 17, 2024StifelBuy—
May 3, 2024Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026

CONCORD, Calif., October 19, 2026--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Yahoo · Oct 14, 2026

Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting

CONCORD, Calif., October 14, 2026--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from aroun

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By